☆ 4.7 Letter

Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees

CLINICAL INFECTIOUS DISEASES (2022)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella et al.

Summary: The BBV152 vaccine demonstrated tolerable safety outcomes and enhanced immune responses in this clinical trial, leading to selection of both Algel-IMDG formulations for phase 2 immunogenicity trials. Further efficacy trials are warranted to validate the vaccine's effectiveness.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Public, Environmental & Occupational Health

Isolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India: VUI-202012/01 of the B.1.1.7 lineage

Pragya D. Yadav et al.

Summary: Researchers have identified a new variant of the severe acute respiratory syndrome coronavirus-2 from COVID-19 cases that travelled from the UK to India in December 2020, highlighting the importance of strengthening surveillance systems to prevent local transmission of this new variant.

JOURNAL OF TRAVEL MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal